AZD5462

DRUG7 trials

Sponsors

AstraZeneca AB, AstraZeneca

Conditions

Chronic Heart FailureHealthy ParticipantsHeart FailureRenal Impairment

Phase 1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD5462 Following Single and Multiple Ascending Dose Administration to Healthy Volunteers

CompletedNCT04994106

AstraZenecaHealthy Participants

Start: 2021-07-27End: 2022-09-20Updated: 2022-10-05

A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

CompletedNCT05395117

AstraZenecaHealthy Participants

Start: 2022-06-30End: 2022-09-12Updated: 2023-12-13

A Bioavailability and Food Effect Study of AZD5462 in Healthy Volunteers

CompletedNCT05512806

AstraZenecaHealthy Participants

Start: 2022-08-24End: 2022-11-07Updated: 2023-11-09

A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment

TerminatedNCT06639087

AstraZenecaHeart Failure, Renal Impairment

Start: 2024-09-27End: 2025-05-29Updated: 2025-09-24

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal Impairment

CompletedNCT06661733

AstraZenecaRenal Impairment

Start: 2024-11-18End: 2024-12-23Updated: 2025-12-03

Phase 2

A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure

CompletedNCT06299826

AstraZenecaChronic Heart Failure

Start: 2024-06-04End: 2026-02-10Updated: 2026-02-18

A Phase IIb Two-cohort, Randomised, Placebo-controlled, Double-blind, Multi-centre, Dose-ranging Study of AZD5462 in Stable Patients with Chronic Heart Failure

CompletedCTIS2023-510148-19-00

AstraZeneca ABChronic Heart Failure

Start: 2024-07-03End: 2026-01-21Target: 235Updated: 2025-12-01